Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OncoVanta Therapeutics, Inc. ("OncoVanta"), a company located in Hagerstown, Maryland, the United States of America.
What this item does
The short version, using the agency's own summary text.
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OncoVanta Therapeutics, Inc. ("OncoVanta"), a company located in Hagerstown, Maryland, the United States of America.
Notice.
Important dates
The dates that matter most for this item.
Published
May 6, 2026
Comment deadline
May 21, 2026
Who published it
The agencies listed in the official filing.